{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:15:09Z","timestamp":1791238509248,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chemerin, an adipokine involved in immune regulation and inflammation, has been implicated in the pathogenesis of inflammatory bowel disease (IBD), including Crohn\u2019s disease (CD) and ulcerative colitis (UC). However, existing studies have reported inconsistent findings regarding its diagnostic value. This meta-analysis aimed to clarify the association between blood chemerin levels and IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) up to February 10, 2024. Observational studies comparing blood chemerin levels between IBD patients and healthy controls, or between active and non-active IBD, were included. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random-effects model by incorporating the possible influence of the heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ten case-control studies with 18 datasets involving 799 CD patients, 520 UC patients, 609 healthy controls, were included. Compared with healthy controls, IBD patients had significantly higher blood chemerin levels (SMD: 0.61, 95% CI: 0.46\u20130.76,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; I\u00b2 = 48%). This association remained consistent across subgroups by disease type, study quality score, study region, and BMI matching (\n                      <jats:italic>p<\/jats:italic>\n                      for subgroup difference all &gt;\u20090.05). Furthermore, chemerin levels were higher in active versus non-active IBD patients (SMD: 0.36, 95% CI: 0.15\u20130.57,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001; I\u00b2 = 38%), with robust findings across subgroup and sensitivity analyses. No significant publication bias was detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Elevated blood chemerin levels are associated with both the presence and activity of IBD, supporting its potential role as a non-invasive biomarker for disease diagnosis and monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04132-2","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:19:23Z","timestamp":1758881963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chemerin as a biomarker of inflammatory bowel diseases: a meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Zhi","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichun","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"6","key":"4132_CR1","first-page":"e41120","volume":"15","author":"MA Muzammil","year":"2023","unstructured":"Muzammil MA, Fariha F, Patel T, Sohail R, Kumar M, Khan E, Khanam B, Kumar S, Khatri M, Varrassi G, et al. Advancements in inflammatory bowel disease: A narrative review of diagnostics, management, epidemiology, prevalence, patient outcomes, quality of life, and clinical presentation. Cureus. 2023;15(6):e41120.","journal-title":"Cureus"},{"issue":"Suppl 3","key":"4132_CR2","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1\u2013106.","journal-title":"Gut"},{"key":"4132_CR3","doi-asserted-by":"crossref","unstructured":"Kellermann L, Riis LB. A close view on histopathological changes in inflammatory bowel disease, a narrative review. Dig Med Res. 2021;4.","DOI":"10.21037\/dmr-21-1"},{"issue":"1","key":"4132_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, Sadeghi A, Nixon MR, Abdoli A, Abolhassani H, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Supplement2","key":"4132_CR5","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","volume":"18","author":"B Caron","year":"2024","unstructured":"Caron B, Honap S, Peyrin-Biroulet L. Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies. J Crohns Colitis. 2024;18(Supplement2):ii3\u201315.","journal-title":"J Crohns Colitis"},{"key":"4132_CR6","doi-asserted-by":"crossref","unstructured":"Sato Y, Tsujinaka S, Miura T, Kitamura Y, Suzuki H, Shibata C. Inflammatory bowel disease and colorectal cancer: epidemiology, etiology, surveillance, and management. Cancers (Basel). 2023;15(16).","DOI":"10.3390\/cancers15164154"},{"issue":"6","key":"4132_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s40261-024-01364-0","volume":"44","author":"C Niu","year":"2024","unstructured":"Niu C, Zhang J, Napel M, Boppana LKT, Anas H, Jadhav N, Dunnigan K, Okolo PI 3. Systematic review with Meta-analysis: efficacy and safety of Upadacitinib in managing Moderate-to-Severe crohn\u2019s disease and ulcerative colitis. Clin Drug Investig. 2024;44(6):371\u201385.","journal-title":"Clin Drug Investig"},{"issue":"2","key":"4132_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/1319-3767.129473","volume":"20","author":"M Mosli","year":"2014","unstructured":"Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol. 2014;20(2):81\u2013101.","journal-title":"Saudi J Gastroenterol"},{"issue":"4","key":"4132_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.metabol.2008.11.011","volume":"58","author":"K M\u00fcssig","year":"2009","unstructured":"M\u00fcssig K, Staiger H, Machicao F, Thamer C, Machann J, Schick F, Claussen CD, Stefan N, Fritsche A, H\u00e4ring HU. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study. Metabolism. 2009;58(4):519\u201324.","journal-title":"Metabolism"},{"issue":"2","key":"4132_CR10","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1530\/JOE-18-0174","volume":"238","author":"G Helfer","year":"2018","unstructured":"Helfer G, Wu QF. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018;238(2):R79\u201394.","journal-title":"J Endocrinol"},{"key":"4132_CR11","doi-asserted-by":"publisher","first-page":"4574509","DOI":"10.1155\/2020\/4574509","volume":"2020","author":"J Li","year":"2020","unstructured":"Li J, Lu Y, Li N, Li P, Wang Z, Ting W, Liu X, Wu W. Chemerin: A potential regulator of inflammation and metabolism for chronic obstructive pulmonary disease and pulmonary rehabilitation. Biomed Res Int. 2020;2020:4574509.","journal-title":"Biomed Res Int"},{"key":"4132_CR12","doi-asserted-by":"crossref","unstructured":"Laffranchi M, Schioppa T, Sozio F, Piser\u00e0 A, Tiberio L, Salvi V, Bosisio D, Musso T, Sozzani S. Del prete A: chemerin in immunity. J Leukoc Biol. 2024:qiae181.","DOI":"10.1093\/jleuko\/qiae181"},{"key":"4132_CR13","doi-asserted-by":"crossref","unstructured":"Tan L, Lu X, Danser AHJ, Verdonk K. The role of chemerin in metabolic and cardiovascular disease: A literature review of its physiology and pathology from a nutritional perspective. Nutrients. 2023;15(13).","DOI":"10.3390\/nu15132878"},{"issue":"11","key":"4132_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.tem.2010.08.001","volume":"21","author":"MC Ernst","year":"2010","unstructured":"Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010;21(11):660\u20137.","journal-title":"Trends Endocrinol Metab"},{"key":"4132_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.peptides.2018.08.012","volume":"108","author":"M Sochal","year":"2018","unstructured":"Sochal M, Mosi\u0144ska P, Fichna J. Diagnostic value of chemerin in lower Gastrointestinal diseases\u2014a review. Peptides. 2018;108:19\u201324.","journal-title":"Peptides"},{"issue":"4","key":"4132_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/cmi.2014.14","volume":"11","author":"C Buechler","year":"2014","unstructured":"Buechler C. Chemerin, a novel player in inflammatory bowel disease. Cell Mol Immunol. 2014;11(4):315\u20136.","journal-title":"Cell Mol Immunol"},{"key":"4132_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cca.2020.02.008","volume":"504","author":"D Jacenik","year":"2020","unstructured":"Jacenik D, Fichna J. Chemerin in immune response and Gastrointestinal pathophysiology. Clin Chim Acta. 2020;504:146\u201353.","journal-title":"Clin Chim Acta"},{"key":"4132_CR18","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3389\/fimmu.2018.01974","volume":"9","author":"C Weidinger","year":"2018","unstructured":"Weidinger C, Ziegler JF, Letizia M, Schmidt F, Siegmund B. Adipokines and their role in intestinal inflammation. Front Immunol. 2018;9:1974.","journal-title":"Front Immunol"},{"issue":"29","key":"4132_CR19","doi-asserted-by":"publisher","first-page":"e2205574119","DOI":"10.1073\/pnas.2205574119","volume":"119","author":"Y Lin","year":"2022","unstructured":"Lin Y, Cai Q, Luo Y, Li B, Chen Y, Yang X, Xuan Y, Yang H, He R. Epithelial chemerin-CMKLR1 signaling restricts microbiota-driven colonic neutrophilia and tumorigenesis by up-regulating lactoperoxidase. Proc Natl Acad Sci U S A. 2022;119(29):e2205574119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4132_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/cmi.2014.15","volume":"11","author":"Y Lin","year":"2014","unstructured":"Lin Y, Yang X, Yue W, Xu X, Li B, Zou L, He R. Chemerin aggravates DSS-induced colitis by suppressing M2 macrophage polarization. Cell Mol Immunol. 2014;11(4):355\u201366.","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"4132_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ibd.21091","volume":"16","author":"J Weigert","year":"2010","unstructured":"Weigert J, Obermeier F, Neumeier M, Wanninger J, Filarsky M, Bauer S, Aslanidis C, Rogler G, Ott C, Sch\u00e4ffler A, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in crohn\u2019s disease. Inflamm Bowel Dis. 2010;16(4):630\u20137.","journal-title":"Inflamm Bowel Dis"},{"issue":"30","key":"4132_CR22","first-page":"6439","volume":"32","author":"YP Gong","year":"2011","unstructured":"Gong YP, Zhang XL. Serum chemerin levels and their clinical significance in patients with crohn\u2019s disease. Jinlin Med J. 2011;32(30):6439\u201340.","journal-title":"Jinlin Med J"},{"key":"4132_CR23","doi-asserted-by":"crossref","unstructured":"Terzoudis S, Malliaraki N, Damilakis J, Dimitriadou DA, Zavos C, Koutroubakis IE. Chemerin, visfatin, and Vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2016;28(7).","DOI":"10.1097\/MEG.0000000000000617"},{"issue":"21","key":"4132_CR24","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.11569\/wcjd.v25.i21.1952","volume":"25","author":"F Xu","year":"2017","unstructured":"Xu F, Liu F. Diagnostic value of chemerin and fecal calprotectin in active inflammatory bowel disease. World Chin J Digest. 2017;25(21):1952\u20138.","journal-title":"World Chin J Digest"},{"issue":"1","key":"4132_CR25","first-page":"85","volume":"26","author":"Y Lu","year":"2021","unstructured":"Lu Y, Tao DX, He ML. Expression of serum adipocytokines, visfatin, and IL-33 and their correlation with gut microbiota in patients with inflammatory bowel disease. Mod Digest Interv. 2021;26(1):85\u201390.","journal-title":"Mod Digest Interv"},{"issue":"14","key":"4132_CR26","first-page":"2653","volume":"22","author":"H Yang","year":"2022","unstructured":"Yang H, Zhang MG, Wang ZD, Zhou M, Ren HF, Wang Y. Correlation of serum Immune-Inflammation-Related protein complexes, 25-Hydroxyvitamin D, and chemerin with disease activity and gut microbiota in patients with inflammatory bowel disease. Progress Mod Biomed. 2022;22(14):2653\u20137.","journal-title":"Progress Mod Biomed"},{"issue":"5","key":"4132_CR27","first-page":"310","volume":"44","author":"HG Li","year":"2024","unstructured":"Li HG, Qin JS. Association of iirpcs, CCL11, and chemerin levels with recurrence of inflammatory bowel disease. Int J Dig Dis. 2024;44(5):310\u20136.","journal-title":"Int J Dig Dis"},{"issue":"7","key":"4132_CR28","first-page":"405","volume":"15","author":"W Gu","year":"2010","unstructured":"Gu W, Pang Z, Huangfu Z, Hua J, Zhou CL, Shen BW. Serum chemerin level and its clinical significance in patients with active inflammatory bowel disease. Chin J Gastroenterol. 2010;15(7):405\u20137.","journal-title":"Chin J Gastroenterol"},{"issue":"22","key":"4132_CR29","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.3748\/wjg.v20.i22.6912","volume":"20","author":"M Waluga","year":"2014","unstructured":"Waluga M, Hartleb M, Boryczka G, Kukla M, Zwirska-Korczala K. Serum adipokines in inflammatory bowel disease. World J Gastroenterol. 2014;20(22):6912\u20137.","journal-title":"World J Gastroenterol"},{"key":"4132_CR30","doi-asserted-by":"crossref","unstructured":"Sochal M, Fichna J, Gabryelska A, Talar-Wojnarowska R, Bia\u0142asiewicz P, Ma\u0142ecka-Wojciesko E. Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy. J Clin Med. 2021;10(19).","DOI":"10.3390\/jcm10194615"},{"issue":"2","key":"4132_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14218\/JTG.2024.00017","volume":"2","author":"S Bencardino","year":"2024","unstructured":"Bencardino S, D\u2019Amico F, Zilli A, Parigi TL, Allocca M, Fiorino G, Danese S, Furfaro F. Fecal, blood, and urinary biomarkers in inflammatory bowel diseases. J Transl Gastroenterol. 2024;2(2):61\u201375.","journal-title":"J Transl Gastroenterol"},{"key":"4132_CR32","doi-asserted-by":"publisher","first-page":"175628482412516","DOI":"10.1177\/17562848241251600","volume":"17","author":"J Clough","year":"2024","unstructured":"Clough J, Colwill M, Poullis A, Pollok R, Patel K, Honap S. Biomarkers in inflammatory bowel disease: a practical guide. Th Adv Gastroenterol. 2024;17:17562848241251600.","journal-title":"Th Adv Gastroenterol"},{"key":"4132_CR33","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"4132_CR34","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.","journal-title":"BMJ"},{"key":"4132_CR35","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V. Cochrane handbook for systematic reviews of interventions version 6.2. Cochrane Collab 2021. www.training.cochrane.org\/handbook"},{"key":"4132_CR36","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010.\u00a0https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"11","key":"4132_CR37","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"7109","key":"4132_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"7650","key":"4132_CR39","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"10","key":"4132_CR40","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20081736","volume":"205","author":"T Yoshimura","year":"2008","unstructured":"Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J Exp Med. 2008;205(10):2187\u201390.","journal-title":"J Exp Med"},{"issue":"1","key":"4132_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/imm.12939","volume":"155","author":"LS Celiberto","year":"2018","unstructured":"Celiberto LS, Graef FA, Healey GR, Bosman ES, Jacobson K, Sly LM, Vallance BA. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut Microbiome. Immunology. 2018;155(1):36\u201352.","journal-title":"Immunology"},{"key":"4132_CR42","doi-asserted-by":"crossref","unstructured":"Mousa RS, Invernizzi P, Mousa HS. Innate immune cells in the pathogenesis of inflammatory bowel disease - from microbial metabolites to immune modulation. Front Gastroenterol. 2024;3.","DOI":"10.3389\/fgstr.2024.1452430"},{"key":"4132_CR43","doi-asserted-by":"publisher","first-page":"e5494","DOI":"10.7717\/peerj.5494","volume":"6","author":"HJ Dranse","year":"2018","unstructured":"Dranse HJ, Zheng A, Comeau AM, Langille MGI, Zabel BA, Sinal CJ. The impact of chemerin or chemokine-like receptor 1 loss on the mouse gut Microbiome. PeerJ. 2018;6:e5494.","journal-title":"PeerJ"},{"key":"4132_CR44","doi-asserted-by":"crossref","unstructured":"Karaskova E, Velganova-Veghova M, Geryk M, Foltenova H, Kucerova V, Karasek D. Role of adipose tissue in inflammatory bowel disease. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22084226"},{"issue":"10","key":"4132_CR45","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1210\/en.2007-0175","volume":"148","author":"K Bozaoglu","year":"2007","unstructured":"Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, Walder K, Segal D. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007;148(10):4687\u201394.","journal-title":"Endocrinology"},{"issue":"2","key":"4132_CR46","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2017","unstructured":"Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110\u201321.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"4132_CR47","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/oby.21735","volume":"25","author":"S Zylla","year":"2017","unstructured":"Zylla S, Pietzner M, K\u00fchn JP, V\u00f6lzke H, D\u00f6rr M, Nauck M, Friedrich N. Serum chemerin is associated with inflammatory and metabolic parameters-results of a population-based study. Obes (Silver Spring). 2017;25(2):468\u201375.","journal-title":"Obes (Silver Spring)"},{"key":"4132_CR48","doi-asserted-by":"publisher","first-page":"677957","DOI":"10.3389\/fimmu.2021.677957","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Bai X, Cao W, Ji J, Wang L, Yang Y, Yang H. The influence of corticosteroids, immunosuppressants and biologics on patients with inflammatory bowel diseases, psoriasis and rheumatic diseases in the era of COVID-19: A review of current evidence. Front Immunol. 2021;12:677957.","journal-title":"Front Immunol"},{"issue":"6","key":"4132_CR49","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ajg.2015.120","volume":"110","author":"MH Mosli","year":"2015","unstructured":"Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and Meta-Analysis. Am J Gastroenterol. 2015;110(6):802\u201319. quiz 820.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04132-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04132-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:51:48Z","timestamp":1781614308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-025-04132-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4132"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04132-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"662"}}